Key Development
Vietnam has roughly 84 linear accelerators serving a cancer system that records more than 180,000 new cases annually. But the more important number is not 84 — it is how many patients can actually receive radiotherapy at the clinically appropriate time.
Tuoi Tre reported that some domestic estimates place current radiotherapy capacity at roughly 60–70% of basic demand, while Ministry of Health materials citing IAEA data have previously suggested only 25–50%, depending on methodology and timing. At Ho Chi Minh City Oncology Hospital, approximately 700 patients are treated each day while another 800–1,000 remain in the queue; machines reportedly operate across three shifts from around 5 a.m. to 11 p.m.
The pressure is structural rather than temporary. GLOBOCAN 2022 estimated 180,480 new cancer cases and 120,184 cancer deaths in Vietnam, while population ageing and improving diagnosis are likely to increase treatment demand further.
Why It Matters
- Radiotherapy is core cancer infrastructure. It sits alongside surgery and systemic therapy as one of the major treatment modalities.
- Waiting time can carry clinical consequences. Radiotherapy often needs to occur within a defined sequence alongside chemotherapy or surgery, making delays more than a convenience problem.
- Vietnam’s own policy ambition is materially higher than today’s installed base. A 2026 national strategy targets 1–2 radiotherapy accelerators per million people by 2035, alongside a more geographically balanced radiotherapy network.
- New technology can raise throughput, but only if the workflow around it scales. New Versa HD systems at Vietnam’s National Cancer Hospital can reduce treatment delivery time in some workflows from roughly ten minutes to two or three, but they still depend on simulation, planning, quality assurance and specialist staff.
Healthcare Insight Analysis
Healthcare Insight believes the wrong equation is:
84 machines today + another 35–40 machines = the radiotherapy shortage solved.
A linear accelerator does not generate treatment capacity by itself.
Its effective output depends on radiation oncologists, medical physicists, radiation therapists, CT simulation, treatment-planning systems, quality assurance, maintenance and reliable procurement operating as one system.
That means Vietnam should shift from measuring installed machines to measuring effective treatment capacity.
One accelerator running 14–18 hours per day with strong uptime and streamlined planning is fundamentally different from another that experiences repeated downtime or lacks enough specialist staff. Tuoi Tre cited international IAEA survey ranges of around 21–30 patients per machine per day, while some Vietnamese sites are treating more than 50.
That is simultaneously a productivity signal and a resilience warning.
The second issue is geographic architecture.
Vietnam does not necessarily need a highly complex radiation-oncology center in every province. A stronger model may be a hub-and-spoke network: regional oncology hubs deliver SRS, SBRT and complex cases; satellite centers perform standard fractionated treatment; imaging and treatment plans can be reviewed remotely.
This matters because equipment alone may not reverse patient flows. Tuoi Tre noted that patients can continue concentrating at tertiary hospitals even where equipment exists locally if confidence in lower-level capability remains limited.
The third issue is capital structure.
A radiotherapy investment is not simply the purchase price of a machine. It includes shielding infrastructure, software, electricity, service contracts, replacement cycles and expensive downtime.
Hospitals cited in the report identified procurement procedures, price appraisal and unresolved frameworks for leasing or public-private cooperation as barriers even when demand is clear.
Vietnam therefore needs to plan radiotherapy capacity, not merely procure radiotherapy equipment.
That distinction has major implications for the private sector.
For medtech companies, the opportunity extends beyond accelerators into service, uptime guarantees, remote support, software, AI-assisted contouring and workforce development. For hospitals, procurement decisions should increasingly be evaluated through cost per treated patient and lifecycle utilization, rather than capital cost alone.
Market Implications
Hospitals: capital planning should focus on patients per machine, operating hours, uptime and queue reduction rather than machine count.
Medtech: value pools extend into maintenance, planning software, AI contouring, CT simulation and QA systems.
Workforce: medical physics and radiation-therapy staffing may become one of the biggest constraints on national expansion.
Payers and policymakers: reimbursement models need to recognize planning, QA, maintenance and technology renewal, not only each delivered radiation fraction.
ANALYTICAL MATRIX
| Dimension | Current Signal | Opportunity | KPI to Track |
| Equipment | ~84 accelerators | 1–2 machines/million by 2035 | Active machines/million |
| Throughput | Some centers >50 patients/day/machine | Workflow optimization | Patients/day, utilization |
| Access | Tertiary-center congestion | Regional hub-and-spoke network | Waiting time |
| Workforce | Uneven specialist capacity | Physics/therapist training | Staff per machine |
| Operations | Procurement and maintenance friction | Lifecycle service models | Uptime and downtime |
The two metrics that matter most over the next five years are median time from radiotherapy indication to first treatment and actual machine uptime/utilization.
Counting machines tells Vietnam how much equipment it has purchased. Measuring those two outcomes tells the healthcare system something much more important: how much cancer-treatment capacity it has actually created.